Trial Profile

A phase II clinical trial to evaluate Camsirubicin (GPX-150) in patients with advanced soft tissue sarcoma (ASTS)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 20 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camsirubicin (Primary) ; Doxorubicin
Indications Soft tissue sarcoma
Focus Therapeutic Use

Most Recent Events

13 May 2021 According to Monopar Therapeutics, company is currently unable to gain regulatory approval to initiate this trial in Spain, thus company evaluating alternative to move to dose escalation run-in clinical trial forward outside of Spain. The company plans to initiate the run-in clinical trial in second half of 2021 in the U.S or another country.
22 Dec 2020 According to a Monopar Therapeutics media release, this study is expected to begin in early 2021 .
12 Nov 2020 According to a Monopar Therapeutics media release, this study is expected to begin at the end of 2020 or in early 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com